Irhythm Technologies Inc (NASDAQ:IRTC) Director Vijay K. Lathi sold 114,018 shares of Irhythm Technologies stock in a transaction on Friday, March 9th. The shares were sold at an average price of $66.44, for a total value of $7,575,355.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Shares of Irhythm Technologies Inc (NASDAQ IRTC) opened at $64.52 on Wednesday. Irhythm Technologies Inc has a 1 year low of $32.10 and a 1 year high of $68.07. The company has a debt-to-equity ratio of 0.41, a quick ratio of 5.64 and a current ratio of 5.72. The stock has a market capitalization of $1,480.00 and a PE ratio of -50.02.
Irhythm Technologies (NASDAQ:IRTC) last posted its quarterly earnings results on Wednesday, February 14th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.35) by ($0.13). Irhythm Technologies had a negative net margin of 29.87% and a negative return on equity of 34.44%. The firm had revenue of $28.20 million for the quarter, compared to analysts’ expectations of $26.79 million. During the same period last year, the firm posted ($0.37) EPS. Irhythm Technologies’s revenue was up 50.8% on a year-over-year basis. equities research analysts forecast that Irhythm Technologies Inc will post -1.53 EPS for the current year.
IRTC has been the subject of a number of recent analyst reports. BidaskClub raised Irhythm Technologies from a “hold” rating to a “buy” rating in a research report on Thursday, February 22nd. Canaccord Genuity reaffirmed a “buy” rating and issued a $80.00 price objective (up previously from $68.00) on shares of Irhythm Technologies in a research report on Monday. ValuEngine raised Irhythm Technologies from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Dougherty & Co initiated coverage on Irhythm Technologies in a research report on Friday, December 1st. They issued a “neutral” rating for the company. Finally, Royal Bank of Canada initiated coverage on Irhythm Technologies in a research report on Monday, December 4th. They issued an “outperform” rating and a $79.00 price objective for the company. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $70.83.
About Irhythm Technologies
iRhythm Technologies, Inc is a United States-based digital health company. The Company develops and commercializes solutions that integrate biosensor technology, patient data, analytics and medical expertise. The Company offers flagship solution, the ZIO Service. Its ZIO Service consists of the ZIO XT Patch, algorithms and the ZIO Report.
Receive News & Ratings for Irhythm Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Irhythm Technologies and related companies with MarketBeat.com's FREE daily email newsletter.